Episurf Medical enters into distribution agreement for Australia and New Zealand

Report this content

Episurf Medical (Nasdaq: EPIS B) today announces that the company has appointed Siaca Medical PTY Ltd (https://www.surgicore.com.au) as distributor in Australia and New Zealand for Episurf Medical’s implant technology, including the Episealer® Knee and the Episealer® Talus. Siaca Medical is a medical devices distributor that focuses on the Australian and New Zealand markets, with headquarters in Sydney, Australia. Episurf Medical is currently engaged in regulatory work in the region. Sales start in Australia is expected in 2022, while for New Zealand, sales start is expected to take place in 2021. 

“These are highly interesting orthopaedic markets, and we are pleased with having a strong partner on the ground. We are currently focusing on the regulatory work leading to market access, and we hope to be able to offer our products to orthopaedic surgeons in the region as soon as possible”, says Pål Ryfors, CEO Episurf Medical. 

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.